Key Details
Price
$420.00Annual ROE
22.99%Beta
0.65Events Calendar
Next earnings date:
Feb 05, 2025Recent quarterly earnings:
Nov 04, 2024Recent annual earnings:
Feb 05, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Aug 24, 2000Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Vertex Pharmaceuticals (VRTX) finished the last trading day at $416.96, which is a decrease of 1.72% compared to the day before.
Levi & Korsinsky has informed investors that it is starting an investigation into Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for potential breaches of federal securities laws. This comes after the company announced unsatisfactory results from its RewinD-LB Phase 2b clinical trial for the pain medication suzetrigine on December 19, 2024.
Vertex (VRTX) has recently caught the attention of Zacks.com users. Therefore, it's important to look into what the future holds for this stock.
Levi & Korsinsky has informed investors that it is starting an investigation into Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for potential breaches of federal securities laws. This comes after the company announced unsatisfactory results from its RewinD-LB Phase 2b clinical trial for the pain medication suzetrigine on December 19, 2024.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will take part in the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 10:30 AM ET. The company will be represented by several key executives, including Dr. Reshma Kewalramani, the President and CEO, and Charlie Wagner, the Chief Financial Officer. Jessica Fye from J.P. Morgan will also be participating in the conference call.
Levi & Korsinsky has informed investors that it is starting an investigation into Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for potential breaches of federal securities laws. This comes after the company announced unsatisfactory results from its RewinD-LB Phase 2b clinical trial for the pain medication suzetrigine on December 19, 2024.
On the most recent trading day, Vertex Pharmaceuticals (VRTX) closed at $402.49, which is a decrease of 1.13% compared to the day before.
Levi & Korsinsky has informed investors that it is starting an investigation into Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for potential breaches of federal securities laws. This comes after the company announced unsatisfactory results from its RewinD-LB Phase 2b clinical trial for the pain medication suzetrigine on December 19, 2024.
Vertex (VRTX) has been getting a lot of interest from users on Zacks.com recently. As a result, it's important to understand the factors that could affect the stock's future.
In the most recent trading session, Vertex Pharmaceuticals (VRTX) finished at $402.70, which is an increase of 0.84% compared to the day before.
FAQ
- What is the primary business of Vertex Pharmaceuticals Incorporated?
- What is the ticker symbol for Vertex Pharmaceuticals Incorporated?
- Does Vertex Pharmaceuticals Incorporated pay dividends?
- What sector is Vertex Pharmaceuticals Incorporated in?
- What industry is Vertex Pharmaceuticals Incorporated in?
- What country is Vertex Pharmaceuticals Incorporated based in?
- When did Vertex Pharmaceuticals Incorporated go public?
- Is Vertex Pharmaceuticals Incorporated in the S&P 500?
- Is Vertex Pharmaceuticals Incorporated in the NASDAQ 100?
- Is Vertex Pharmaceuticals Incorporated in the Dow Jones?
- When was Vertex Pharmaceuticals Incorporated's last earnings report?
- When does Vertex Pharmaceuticals Incorporated report earnings?
- Should I buy Vertex Pharmaceuticals Incorporated stock now?